{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:51:52Z","timestamp":1791082312253,"version":"4.1.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Anifrolumab is a monoclonal antibody that targets the type I interferon receptor subunit 1. It was approved for the treatment of systemic lupus erythematosus by the US Food and Drug Administration in 2021 and by the European Medicines Agency in 2022. Although phase III clinical trials reported a statistically significant improvement in skin lesions, anifrolumab has not yet been approved for the treatment of cutaneous lupus erythematosus. We present a case series that includes 10 patients with cutaneous lupus erythematosus who demonstrated a rapid and sustained response to anifrolumab.<\/jats:p>","DOI":"10.1093\/ced\/llaf272","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T17:12:16Z","timestamp":1751044336000},"page":"2040-2043","source":"Crossref","is-referenced-by-count":3,"title":["Anifrolumab for the treatment of cutaneous lupus erythematosus: a 10-case series"],"prefix":"10.1093","volume":"50","author":[{"given":"Maria Elena","family":"Hern\u00e1ndez-Salas","sequence":"first","affiliation":[{"name":"Dermatology Department, Fuenlabrada University Hospital , Fuenlabrada, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Horcajada-Reales","sequence":"additional","affiliation":[{"name":"Dermatology Department, Fuenlabrada University Hospital , Fuenlabrada, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Palomar-Prieto","sequence":"additional","affiliation":[{"name":"Dermatology Department, Fuenlabrada University Hospital , Fuenlabrada, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fern\u00e1ndez-de\u00a0la\u00a0Fuente","sequence":"additional","affiliation":[{"name":"Dermatology Department, Fuenlabrada University Hospital , Fuenlabrada, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Herrero-Ruiz","sequence":"additional","affiliation":[{"name":"Dermatology Department, Fuenlabrada University Hospital , Fuenlabrada, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mart\u00ednez-Lauwers Dolz","sequence":"additional","affiliation":[{"name":"Dermatology Department, Fuenlabrada University Hospital , Fuenlabrada, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Romero-Mat\u00e9","sequence":"additional","affiliation":[{"name":"Dermatology Department, Fuenlabrada University Hospital , Fuenlabrada, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"2025092509015143800_llaf272-B1","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"TULIP-1 study investigators. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025092509015143800_llaf272-B2","doi-asserted-by":"crossref","first-page":"e001007","DOI":"10.1136\/lupus-2023-001007","article-title":"Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE","volume":"10","author":"Bao","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2025092509015143800_llaf272-B3","first-page":"e39553","article-title":"Role of anifrolumab in refractory cutaneous manifestations of lupus erythematosus: a case series and literature review","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"2025092509015143800_llaf272-B4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdcr.2023.04.024","article-title":"Successful treatment of severe chronic cutaneous lupus with anifrolumab: a series of 6 cases","volume":"37","author":"Kowalski","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2025092509015143800_llaf272-B5","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.3390\/biomedicines11112904","article-title":"Anifrolumab for moderate and severe muco-cutaneous lupus erythematosus: a monocentric experience and review of the current literature","volume":"11","author":"Paolino","year":"2023","journal-title":"Biomedicines"},{"key":"2025092509015143800_llaf272-B6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11882-020-00906-8","article-title":"Cutaneous lupus erythematosus: progress and challenges","volume":"20","author":"Petty","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"2025092509015143800_llaf272-B7","doi-asserted-by":"crossref","first-page":"T55","DOI":"10.1016\/j.ad.2024.10.008","article-title":"Use of anifrolumab in systemic lupus erythematosus, cutaneous lupus erythematosus, and other autoimmune dermatoses","volume":"116","author":"Mart\u00edn-Torregrosa","year":"2025","journal-title":"Actas Dermosifiliogr"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf272\/63528644\/llaf272.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/10\/2040\/63528644\/llaf272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/10\/2040\/63528644\/llaf272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:01:57Z","timestamp":1758805317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/10\/2040\/8169430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":7,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,19]]},"published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf272","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,19]]}}}